that’s probably in-line with the past, won’t disagree
It’s just I’m noticing really violent recoveries from 52 week lows to nearing their 52 week highs for our US peers (small market cap):
- DYN from $4.3 to $14.8 - RNA from $10.9 to $22.6
The big boys like Ionis have been hitting new 52 week highs every other week now.
Almost like the market wants to reward these RNA players in A downtrodden market - as some of these new medicines will displace those existing, or create new revenue streams given unmet demand - so will be shielded from the recession.
But the market will only reward those that can prove out/validate their platforms via strong data points/milestones/scaleable capabilities - so here’s hoping PYC will be recognized as such
the left field is a buyout - we’ve seemed to have entered into a awkward dance with a $512B gorilla that is Roche, who’s back tracing our steps
PYC Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)